Orthofix reported second quarter 2026 results with 5% pro forma constant currency net sales growth and raised its full-year outlook. The company now expects 2026 net sales of $845 million to $855 million and adjusted EBITDA of $95 million to $98 million, reflecting the restoration of Medicare reimbursement for bone growth stimulators and a strategic European distributor arrangement expected to add approximately $15 million in incremental net sales. CEO Massimo Calafiore highlighted double-digit growth in Global Limb Reconstruction and Spine Fixation, sequential improvement in Biologics, and the launch of AccelStim 2.0. CFO Julie Andrews noted that the European distributor deal will create a temporary free cash flow timing headwind in 2026 and an approximately $22 million net sales headwind in 2027. The company continues to face softness among smaller U.S. spine distributors, which is reflected in its second-half outlook.
Orthofix Medical IncRaised 2026 guidance on Medicare reimbursement restoration and European distributor deal, boosting sales outlook.
